Aspirin Use In Heart Patients Increases But Still "Suboptimum" - Study
This article was originally published in The Tan Sheet
Executive Summary
Aspirin usage in outpatients with coronary artery disease without contraindications increased from 5% in 1980 to 26.2% in 1996 in a representative sample of U.S. doctors' office visits, according to a study in the March 14 issue of the American Heart Association journal Circulation.
You may also be interested in...
Bayer Aspirin Ads Revised Under $1 Mil. FTC Settlement
Bayer ads cautioning aspirin therapy "is not appropriate for everyone" and offering a free consumer education brochure will break in February magazines under a $1 mil. settlement reached with the Federal Trade Commission.
Bayer
Print ad in the June 17 New England Journal of Medicine for enteric-coated Bayer aspirin states, "Aspirin should be at the core of prevention. So why aren't more patients on aspirin?" Despite evidence that "aspirin-based therapy reduces vascular events among a broad range of at-risk patients...recent clinical studies and expanded FDA indications, millions of patients for whom aspirin may be appropriate still don't take it as part of their prevention regimen," the ad notes. "No other prevention medication is as affordable as aspirin," the ad concludes
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC